EUVIMEDEUVIMED entdecken
Crossref

Junctional adhesion molecular 3 (JAM3) is a novel tumor suppressor and improves the prognosis in breast cancer brain metastases via the TGF-β/Smad signal pathway

Kaitao Zhu, Shiwei Li, Hongru Yao, Jilong Hei, WenGuo Jiang, Tracey Martin, Shanyi Zhang

Journal of Neuro-Oncology · 2024

DOI: 10.1007/s11060-024-04797-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2024. Verfasst von Kaitao Zhu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Brain Neoplasms, Transforming Growth Factor beta, Signal Transduction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Natural Science Foundation of Guangdong Province, The General Program of Medical Scientific Research Foundation of Guangdong, The Qihang Scientific General Project of Sun Yat-Sen Memorial Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Breast cancer brain metastasis (BCBM) is a deadly clinical problem, and the exact underlying mechanisms remain elusive. Junctional adhesion molecule (JAM), a tight junction protein, is a key negative regulator of cancer cell invasion and metastasis. METHODS: Junction adhesion molecule 3 (JAM3) expression in breast cancer was analyzed using bioinformatics methods and confirmed by PCR, western blotting, and immunofluorescence (IF) in cell lines. The effects of exogenous expression of JAM3 using lentiviral vectors on invasion, adhesion, and apoptosis were verified using transwell assays and flow cytometry. Differentially expressed genes (DEGs) were detected by RNA sequencing and verified by q‒PCR and Western blotting. The effect of JAM3 silencing using siRNA was assessed by an adhesion assay. Kaplan‒Meier analysis was applied to calculate the impact of JAM3 expression and classic clinicopathologic characteristics on survival. RESULTS: Bioinformatics analysis revealed that JAM3 expression was reduced in BCBM. Exogenous expression of JAM3 minimizes the ability of breast cancer cells to invade and adhere and promotes their apoptosis. Silencing JAM3 results in morphology changes and the recovery of invasion and adhesion to ECMs, and the TGF-β/Smad signaling pathway may be involved. JAM3 predicts less metastasis and good survival in patients with BCBM. Statistical analysis of BCBM samples detected by immunohistochemistry (IHC) and the associated clinicopathological characteristics revealed that low levels of JAM3 expression and high levels of TNF-β1 are linked to the clinical progression of both primary and metastatic breast tumors. Kaplan-Meier analysis revealed that a high expression level of JAM3 was associated with longer survival. CONCLUSION: JAM3 can serve as a key negative regulator of breast cancer cell invasion, apoptosis, and brain metastasis, possibly through the TGF/Smad signaling pathway. JAM3 is anticipated to be a promising biomarker for the diagnosis and prognosis of breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBrain NeoplasmsTransforming Growth Factor betaSignal TransductionCell Adhesion MoleculesSmad ProteinsHumansFemalePrognosisBiomarkers, TumorApoptosisGene Expression Regulation, NeoplasticCell ProliferationMiddle AgedCell Line, TumorCell AdhesionNeoplasm Invasiveness

Stichwörter der Autor:innen

Breast cancer brain metastasisECMsInvasionJunction adhesion molecule 3TGF-β1/Smad

Substanzen

Transforming Growth Factor betaCell Adhesion MoleculesSmad ProteinsJAM3 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Neurosurgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong- Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Department of Neurosurgery, HeYou International Health System, Foshan, China.
  • Joint Centre Biomedical Research), School of Medicine, Cardiff China Medical Research Collaborative (CCMRC), (Cardiff University - Peking University Cancer Institute and Cardiff University - Capital Medical University,…
  • Department of Neurosurgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. zsyscience@163.com.
  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong- Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. zs…

Förderung

  • Natural Science Foundation of Guangdong Province
  • The General Program of Medical Scientific Research Foundation of Guangdong
  • The Qihang Scientific General Project of Sun Yat-Sen Memorial Hospital
  • the Key Research and Development Plan Project of Guangzhou
  • Cancer Research Wales(WGJ2013), the CardiffChina Medical Scholar-ship

Zitieren

APA

Zhu, K., Li, S., Yao, H., Hei, J., Jiang, W., Martin, T., & Zhang, S. (2024). Junctional adhesion molecular 3 (JAM3) is a novel tumor suppressor and improves the prognosis in breast cancer brain metastases via the TGF-β/Smad signal pathway. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04797-x

Vancouver

Zhu K, Li S, Yao H, Hei J, Jiang W, Martin T, et al. Junctional adhesion molecular 3 (JAM3) is a novel tumor suppressor and improves the prognosis in breast cancer brain metastases via the TGF-β/Smad signal pathway. Journal of Neuro-Oncology. 2024. doi:10.1007/s11060-024-04797-x

BibTeX
@article{Zhu2024,
  author = {Zhu, Kaitao and Li, Shiwei and Yao, Hongru and Hei, Jilong and Jiang, WenGuo and Martin, Tracey and Zhang, Shanyi},
  title = {Junctional adhesion molecular 3 (JAM3) is a novel tumor suppressor and improves the prognosis in breast cancer brain metastases via the TGF-β/Smad signal pathway},
  journal = {Journal of Neuro-Oncology},
  year = {2024},
  doi = {10.1007/s11060-024-04797-x}
}
Kostenlos starten →